intranasal

Monday, November 04, 2024

NEWS

intranasal

BBIL completes trials for India´s intranasal Covid-19 vaccine

Published on: August 15, 2022
18:45

New Delhi, Aug 15 (Prensa Latina) Bharat Biotech International Limited (BBIL) on Monday announced that its intra-nasal vaccine (BBV154) has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials.

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

Radio – Publications – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado, Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division Prensa Latina.

intranasal

BBIL completes trials for India´s intranasal Covid-19 vaccine

LATEST NEWS